Aberrant expression and hormonal regulation of Galectin-3 in endometriosis women with infertility

Our results suggest that aberrant expres - sion of Gal-3 might contribute to infertility in patients with endometriosis due to progesterone resistance.

Endometriosis · Galectin-3 (Gal-3) · Uterine receptivity · Sex hormone

Endometriosis is a benign gynecological disorder with malignant biological characteristics and is defined by the presence of endometrial glands and stroma outside the uter- ine cavity. Ectopic endometrial cells can spread to pelvic organs such as rectum, bladder, and ovaries. This spread - ing contributes to various clinical manifestations includ - ing irregular uterine bleeding, dyspareunia, chronic pelvic pain, and infertility: a condition affecting 10 % of women of reproductive age [1–3]. Statistically, 30–50 % of females with endometriosis are infertile and 25–50 % of females with infertility have endometriosis [ 4]. Although the asso - ciation between endometriosis and infertility has been well established, the underlying mechanisms remain unknown. It has been proposed that abnormal endometrial devel - opment in patients with endometriosis contributes to endometriosis-related infertility [ 5]. It is well known that endometrial receptivity is vital in women’s fertility. Human tissue and mouse model studies have demonstrated that the molecular markers of endometrial receptivity are altered

Objective To investigate the role and potential molecular mechanism of Galectin-3 (Gal-3) in the etiology of endo - metriosis-associated infertility.

We detected Gal-3 expression in eutopic endo - metrium from women with endometriosis-associated infer - tility and healthy women without endometriosis or infer - tility. We then evaluated Gal-3 expression in endometrial glandular epithelial cells (EECs) and endometrial stromal cells (ESCs) and investigated its response to hormone stim- ulation in EECs and ESCs from both groups of women.

Results of real-time PCR and western blot analysis showed Gal-3 expression in both proliferative and secretory stages of the menstrual cycle decreased significantly in women with endometriosis-associated infertility compared to healthy H. Yang and J. Yin contributed equally to this work. * W. Zhang [email protected] * C. Cheng [email protected] H. Yang [email protected] 1 Department of Reproductive Endocrinology, Obstetrics and Gynecology Hospital, Fudan University, 413 Zhaozhou Road, Shanghai 200011, China 2 Department of Gynecology, Chongqing Ninth People’s Hospital, Chongqing, China 3 Department of Chemical and Biomedical Engineering, University of South Florida, Tampa, FL 33620, USA 4 Department of Medicine, SUNY Downstate Medical Center, New York, NY , USA 5 Department of Genetics, Geisel School of Medicine at Dartmouth, Hanover, NH, USA 786 J Endocrinol Invest (2016) 39:785–791 1 3 in both humans and mice with endometriosis. Integrins, matrix metalloproteinases (MMPs), and homeobox genes (HoxA10) display aberrant expression patterns in the eutopic endometrium of women with endometriosis [6, 7]. Other alterations of biochemical or molecular markers have also been reported, including changes in the levels of vascular endothelial growth factor (VEGF) [8] and inter - leukin 6 (IL-6) [9]. Galectin-3 (Gal-3), a β-galactoside- binding protein, has been related to endometrial receptiv- ity during embryonic implantation recently [10, 11]. Gal-3 with a ~31 kDa lectin contains a collagen-α-like domain, an N-terminal domain, and the carbohydrate recognition domain (CRD) [12]. These three structures allow Gal-3 to possess specific biological functions, including cell adhe- sion, migration, cell-extracellular matrix interactions [13], immune response, [14] and signal transduction [15]. It has been shown that Gal-3 is expressed in many cell types, including endometrial cells and trophoblast cells [16–19]. Previous studies have reported that Gal-3 is specifically expressed in endometrial cells in the secretory phase [10, 20], in placental tissue during early pregnancy, and in decidua surrounding the site of implantation. Due to these findings, we speculated that the expression of Gal-3 might be aberrant in endometriosis patients with infertility. Additionally, Gla-3 has been known as a component of a nuclear and cytoplasmic complex, shuttling between the nucleus and cytoplasm [21]. Estrogen and progesterone belong to the nuclear hormone superfamily transcription fac- tors, which play important role in the formation of receptive endometrium. Furthermore, it has been demonstrated that endometriosis-related infertility is associated with abnormal sex hormone regulation [22]. Thus, it would be interesting to explore whether the expression of Gal-3 is regulated by sex hormones in secondary infertility of endometriosis patients.

Tissue collection We collected endometrial tissue samples from 34 women, aged 28–35 years (mean age 31.51 ± 3.52), who con- sulted for infertility and were found to have surgically and histologically-confirmed endometriosis. As controls, we also collected endometrial biopsy specimens from 34 healthy women aged 30–35 years (mean age 32.55 ± 3.90). Women in the control group underwent tubal sterilization and were laparoscopically confirmed to be free of endome- triosis. These women displayed normal menstrual cycles and had not received anti-inflammatory or hormonal ther - apy within 3 months prior to surgery. The phase of the sub- jects’ menstrual cycle was determined according to the cri- teria of Noyes et al. [23]. The endometrial tissue samples from each group were digested for cell culture, snap frozen and kept under −80 °C for subsequent real-time PCR and western blot analysis, or fixed in 4 % paraformaldehyde for paraffin blocks. Informed consent was obtained in writing from all subjects before surgery. Cell culture Primary proliferative phase endometrial stromal and glan- dular epithelial cells were obtained from six subjects in the endometriosis group and six subjects in the control group. For each subject, secretory phase endometrial stromal and glandular epithelial cells were also obtained. Endometrial tissue was transported from the site of collection to the laboratory in Hanks’ balanced salt solution. The tissue was then minced and digested in Hanks’ balanced salt solution containing 1 % penicillin, 1 % streptomycin, 5 % colla- genase, and 0.5 % deoxyribonuclease at 37 °C for 30 min with agitation. The dispersed endometrial cells were sepa- rated by filtration through a wire sieve (73-mm diameter pore, Sigma). The endometrial glands (largely undispersed) were retained by the sieve, whereas the dispersed stromal cells passed through the sieve into the filtrate. Endometrial glandular epithelial cells (EECs) were plated on Madri- gal coated 12 well-plates, while endometrial stromal cells (ESCs) were plated on plastic 12-well plates. Both types of cells were plated in DMEM/F12 phenol red medium (Gibco Invitrogen,Carlsbad, CA, USA) containing 10 % fetal bovine serum (FBS) (Gibco). Cell cultures were main- tained at 37 °C in a humidified atmosphere (5 % CO 2) and were allowed to replicate to confluence. Thereafter, cells were passaged by standard methods of trypsinization and allowed to replicate to confluence, which required approxi- mately 24–48 h. Cells after first passage were characterized as described previously [24]. Real‑time PCR analysis Total RNA was extracted from 34 samples from the endo- metriosis group and 34 samples from the control group using Trizol Reagent (Invitrogen). Total RNA (1 μg) was reverse transcribed using a PrimeScript RT reagent kit (Takara, Dalian, China). Reverse-transcription PCR was performed prior to quantitative real-time PCR. The mRNA levels were determined by real-time PCR using SYBR Pre- mix Ex Taq (TaKaRa) with the Applied Biosystems 7000 system SDS software as previous described [25]. Glyceral- dehyde 3-phosphate dehydrogenase (GAPDH) was used as an endogenous control to normalize for differences in the amount of total RNA in each sample. The primer sequences and the sizes of the amplified fragments were as follows: Gal-3 (93 bp) 5′-CTT CCA CTT TAA CCC ACG CTT 787J Endocrinol Invest (2016) 39:785–791 1 3 CAA-3′ (sense), 5′-TGT CTT TCT TCC CTT CCC CAG TTA TT-3′ (anti-sense); GAPDH (131 bp) 5′-ATG ACC CCT TCA TTG ACC-3′ (sense), 5′-GAA GAT GGT GAT GGG ATT TC-3′ (anti-sense). Immunohistochemistry The paraffin blocks were cut into sections of 4 μm, mounted on polylysine-coated microslides, dewaxed, and rehydrated. Then, tissue sections were incubated in 3 % hydrogen peroxide at room temperature. For antigen retrieval, tissue slides were immersed in citric acid and boiled in a microwave oven. The sections were washed in distilled water and phosphate buffered saline (PBS, Gibco), and then subjected to bovine serum to block unspe- cific binding agents. This step was followed by overnight exposure (4 °C) to the mouse anti-human Gal-3 antibody (mab1154, R&D Systems Inc., Minneapolis, MN, USA) in a humidified chamber. After being rinsed in PBS, the sec- tions were incubated with the bridging rabbit anti-mouse immunoglobulins conjugated with horseradish peroxidase (HRP)-labelled dextran polymer for 1 h. After washing in PBS, diaminobenizidine tetrahydrochloride (DAB) solu- tion was applied, followed by running tap water as well as nuclear counterstaining with haematoxylin (Sigma, USA). The stained slides were viewed under microscopy (OLYM- PUS OPTICAL CO., Ltd.) under 400× magnification. Positive cells were characterized by the brown staining of Gal-3 antibody. The intensity and distribution of the stain- ing reaction were evaluated by two blinded, independent observers. Western blot Protein samples were extracted from tissues or cells, and the protein concentration was measured by bicinchoninic acid assay (BCA). Samples were run in SDS-PAGE gel, transferred to nitrocellulose membranes, and immunob- lotted overnight with gentle shaking at 4 °C with primary antibodies. The primary antibodies included monoclonal mouse anti-human Gal-3 antibody (1:2500) and mono- clonal mouse anti-human GAPDH (Kangchen, Shanghai, China) antibody (1:5000). This procedure was followed by incubation with horseradish peroxidase-conjugated second- ary antibodies. The reactions were detected by enhanced chemiluminescence assay. GAPDH was used as an endog- enous control for normalization. Hormonal stimulation protocol For the hormone stimulation test, 5 × 10 5 cells in 1 ml of media were plated on a 6-well plate and grown for 24 h in normal medium containing 10 % FBS without antibiotics. Then, the media were replaced by serum-free and phenol red-free culture media for 24 h to prepare for the stimula- tion experiment. Stimulation was performed under vari- ous concentrations of 17β-estradiol (E2, 0, 10 −10–10−6 M, Sigma) alone and under various concentrations of pro- gesterone (P4, 0, 10 −9–10−5 M, Sigma) alone. The same experiment was performed with E2, P4, or E2 combined with P4 (E2P4, 10 −8 M E2, 10−7 M P4, Sigma) for 24, 48, and 72 h. The control was plated in phenol red-free culture media containing charcoal-stripped 10 % FBS (Bioind, Shanghai, China). Statistical analysis Data were expressed in terms of mean ± SEM. One-way ANOV A analyses were performed and least significant dif- ference (LSD) tests were applied for post hoc testing using SPSS software version 15.0 with p < 0.05 considered statis- tically significant.

Gal‑3 expression in endometria of endometriosis and control groups To verify whether expression of Gal-3 is abnormal in the endometria of the endometriosis group, we performed immunochemistry analysis to display the expression pat- tern of Gal-3 proteins in endometria from both the healthy and endometriosis group (Fig. 1). Our results showed that Gal-3 was presented in the endometrium from both the con- trol group (Fig. 1b) and the endometriosis group (Fig. 1c). Then, Gal-3 mRNA expression levels in all endome- trium samples were detected by real-time PCR analysis. As shown in Fig. 2a, Gal-3 showed significantly higher levels of expression in the secretory phase than the proliferative phase, regardless of group. Moreover, during both phases, Gal-3 expression was significantly down-regulated (secre- tory stage 0.47 ± 0.02 vs 0.05 ± 0.01, p < 0.05; prolifera- tive phase 0.26 ± 0.02 vs 0.02 ± 0.01, p < 0.05) in eutopic endometrium from endometriosis patients compared to the normal endometrium. This result was confirmed at the pro- tein level by western blot analysis (Fig. 2b). Gal‑3 expression in epithelial cells and stromal cells of endometria The endometrium becomes receptive to embryonic attach- ment in the secretory phase of the menstrual cycle; thus, we explored whether Gal-3 expression is different in EECs and ESCs during this phase. The results of real- time PCR showed that Gal-3 expression was significantly 788 J Endocrinol Invest (2016) 39:785–791 1 3 down-regulated in EECs from the endometriosis group compared to the healthy group (0.14 ± 0.06 vs 0.59 ± 0.07, p < 0.05) (Fig. 3a). In contrast, there was no significant change in Gal-3 expression in ESCs from the control group compared to the endometriosis group; however, there was a trend of down-regulation of Gal-3 in the endometriosis group. We further confirmed these results by western blot analysis. As shown in Fig. 3b, a significant down-regulation of Gal-3 protein was observed in EECs but not ESCs of eutopic endometrial samples from the endometriosis group compared to the control group (0.22 ± 0.05 vs 0.58 ± 0.07, p < 0.05). Hormone‑stimulated Gal‑3 expression in endometrial epithelial cells To further investigate the hormone regulation of Gal-3 expression in EECs, various concentrations of E2 and P4 were used to co-culture EECs from the control group for 24 h before mRNA levels of Gal-3 were detected. Our

showed that Gal-3 was up-regulated by E2 and P4 at all concentrations, reaching peak level at 10 −8 and 10−7 M, respectively (Fig. 4a, b) Thus, concentrations of 10−8 M of E2 and 10 −7 M of P4 were used in the subse- quent experiments. Then, the expression of Gal-3 was detected in EECs pre- treated with 10 −8 M E2, 10 −7 M P4, or 10 −8 M E2 com- bined with 10−7 M P4 for 24, 48, and 72 h, respectively. In the control group, Gal-3 expression was induced by E2 or P4 treatment in a time dependent manner (Fig. 5a). Expres- sion of Gal-3 in the E2P4 group was lower than that in the P4 treatment group and higher than that in the E2 treatment group. These results suggest Gal-3 induction is more sensi- tive to P4 than E2 treatment; however, in EECs from the eutopic endometria with endometriosis (Fig. 5b), Gal-3 expression increased slightly after hormone pretreatment Fig. 1 Immunohistochemistry analysis of Gal-3 expression. a Nega - tive control. b Secretory phase endometrium from healthy controls. c Secretory phase eutopic endometrium from endometriosis patients with infertility. Mouse IgG was used in the negative control (a), while Gal-3 antibody was used other analyses (b, c) Fig. 2 Gal-3 mRNA and protein expression in endometria samples from patients and healthy women. a Relative expression levels of Gal-3 mRNA in different samples measured by real-time PCR analy- sis. b Relative expression levels of Gal-3 protein in different samples measured by western blot analysis. Expression levels of Gal-3 were normalized against those of GAPDH in matched samples. ES endo- metria of patient with endometriosis in secretory phase, EP endo- metria of patient with endometriosis in proliferative phase, CS endo- metria of controls in secretory phase, CP endometria of controls in proliferative phase, Control control group, EMT endometriosis group; #p < 0.05 789J Endocrinol Invest (2016) 39:785–791 1 3 for 24 h, and then decreased time-dependently. Further - more, compared with the control group, the expression of Gal-3 was lower in the endometriosis groups at all time points.

Endometriosis shows a serious impact on female fertility, but the etiology and pathogenesis of endometriosis-related infertility are unknown. Thus, it is imperative to identify the molecular mechanism of endometriosis to develop an effective therapy for endometriosis patients with infertility. Several studies have reported that endometriosis is a major cause of infertility due to its adverse effect on endometrial receptivity to embryonic implantation [26]. Our previous study verified that Gal-3 plays an impor - tant role in the process of embryonic implantation [25]. Intracellular Gal-3 promoted proliferation and adhe- sion in endometrial cells. Decreased expression of Gal-3 hindered embryonic adhesion to endometrial epithelial cells and delayed proliferation of endometrial stromal cells in achieving optimal status to accommodate the invad- ing embryo, resulting in failed embryonic implantation. Secreted Gal-3 inhibited cell proliferation and induced apoptosis of endometrial cells [27]. This study shows that Gal-3 is expressed in the endometrium of both endometrio- sis and healthy women, but is reduced significantly in the former. This suggests a defect in Gal-3 expression occurs in eutopic endometrium from endometriosis patients with infertility. Decreased Gal-3 expression in eutopic endo- metrium from patients with endometriosis may contribute to the defective formation of receptive endometrium, thus leading to infertility. Hormonal regulation of cellular function impacts many dynamic biological changes occurring during the peri- implantation stage of the menstrual cycle. Estrogen and pro- gesterone act coherently at certain time intervals to stimulate Fig. 3 Expression of Gal-3 mRNA and protein in epithelial cells and stromal cells from secretory phase endometria. a Relative expres- sion levels of Gal-3 mRNA in EECs and ESCs. b Relative expression levels of Gal-3 protein in EECs and ESCs; Ctrl control group, EMT endometriosis group, EECs endometrial glandular epithelial cells, ESCs endometrial stromal cells; #p < 0.05 Fig. 4 Hormonal regulation of Gal-3 expression by E2 and P4 in Endometrial epithelial cells. EECs were treated with E2 (a) (Ctrl, 10 −10–10−6 M) and P4 (b) (Ctrl, 10 −9–10−5M) for 24 h, mRNA level of Gal-3 was determined by real-time PCR. Gal-3 expression was analyzed by real-time PCR and GAPDH was used as an endogenous control to normalize for differences. EECs endometrial glandular epi- thelial cells; #p < 0.05 790 J Endocrinol Invest (2016) 39:785–791 1 3 the expression of key molecules that regulate endometrial receptivity. Our results showed that Gal-3 expression spe- cifically increased during the secretory phase of the men- strual cycle in both groups, indicating that Gal-3 may be regulated by sex hormones. To confirm this relationship, we investigated the effect of hormones on Gal-3 expression in both EECs and ESCs. We found that regulation of Gal-3 expression by E2 and P4 could be detected in EECs but not ESCs. This result indicates that Gal-3 may primarily con- tribute to the dynamic change of EECs during embryonic implantation. Then, we explored the physiological dose of E2 (10 −8 M) and P4 (10−7 M) that maximized Gal-3 expres- sion in EECs. The results suggested that Gal-3 is regulated by sex hormones, which is in agreement with our previous study [27]. In the control group, expression of Gal-3 was significantly increased when induced by P4 alone, compared to E2 alone or E2P4. From these results, we concluded that E2, to some degree, antagonized the increased expression of Gal-3 by P4 in normal endometrium. In the endometriosis group, E2 alone, P4 alone, nor E2P4 could increase Gal-3 expression to the level of the control group. This indicates that there is no induction of Gal-3 expression in response to E2 or P4 treatment in the endometriosis group. Previ- ous reports have shown that progesterone resistance is one important factor for endometriosis. Moreover, Gal-3 can be detected in the peritoneal fluid of endometriosis patients [28–30]; thus, defective progesterone regulation in endome- triosis women with infertility might account for decreased Gal-3 expression in eutopic endometrium. In summary, we found decreased expression of Gal-3 in eutopic endometrium from endometriosis, which may account for the defective formation of receptive endome- trium. We further showed that Gal-3 was regulated mainly by hormones in EECs. We also suggested that the failure of Gal-3 elevation by hormones in EECs from endometri- osis patients may contribute to progesterone resistance in endometriosis-related infertility. Although our study pre- liminarily indicates that the defective expression of Gal-3 may contribute to infertility in patients with endometriosis, further research is needed to detail the pathways of Gal-3 in eutopic endometrium from endometriosis. Acknowledgments This study was supported by the National Natu- ral Science Foundation of China (Grant No. 81300467), the Program of Shanghai Subject Chief Scientist (Grant No. 12XD1401200), and the Programs Foundation of Ministry of Education of China (Grant No. 20120071110074). Compliance with ethical standards Conflict of interest The authors declare no conflict of interest. Ethical approval Consent forms and protocols were approved by the Ethical Committee of Obstetrics and Gynecology Hospital at Fudan University. All procedures performed in studies involving human par- ticipants were in accordance with the ethical standards of the institu- tional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors. Informed consent Informed consent was obtained from all individ- ual participants included in the study. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://crea- tivecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. Fig. 5 Defective progesterone regulation in endometrial epithelial cells from endometriosis women with infertility. EECs from control group (a) and endometriosis group (b) were treated with 10 −8 M E2 with or without 10 −7 M P4 and Gal-3 expression was analyzed at 0, 24, 48, 72 h. Gal-3 expression was analyzed by real-time PCR and GAPDH was used as an endogenous control to normalize for differ - ences. EECs endometrial glandular epithelial cells; #p < 0.05 791J Endocrinol Invest (2016) 39:785–791 1 3

1. Giudice LC, Kao LC (2004) Endometriosis. Lancet 364:1789–1799 2. Gao X, Outley J, Botteman M et al (2006) Economic burden of endometriosis. Fertil Steril 86:1561–1572 3. Cramer DW, Missmer SA (2002) The epidemiology of endo- metriosis. Ann N Y Acad Sci 955:11–22 (discussion 34–16, 396–406) 4. Meuleman C, Vandenabeele B, Fieuws S et al (2009) High prev- alence of endometriosis in infertile women with normal ovula- tion and normospermic partners. Fertil Steril 92:68–74 5. Browne H, Taylor H (2006) HOXA10 expression in ectopic endometrial tissue. Fertil Steril 85:1386–1390 6. Fazleabas AT, Brudney A, Chai D et al (2003) Steroid receptor and aromatase expression in baboon endometriotic lesions. Fertil Steril 80(Suppl 2):820–827 7. Zanatta A, Pereira RM, Rocha AM et al (2015) The relationship among HOXA10, estrogen receptor α, progesterone receptor, and progesterone receptor B proteins in rectosigmoid endome- triosis: a tissue microarray study. Reprod Sci 22:31–37 8. da Silva CM, Vilaça Belo A, Passos Andrade S et al (2014) Iden- tification of local angiogenic and inflammatory markers in the menstrual blood of women with endometriosis. Biomed Pharma- cother 68:899–904 9. Carmona F, Chapron C, Martínez-Zamora MÁ et al (2012) Ovar- ian endometrioma but not deep infiltrating endometriosis is asso- ciated with increased serum levels of interleukin-8 and interleu- kin-6. J Reprod Immunol 95:80–86 10. von Wolff M, Wang X, Gabius HJ et al (2005) Galectin finger - printing in human endometrium and decidua during the men- strual cycle and in early gestation. Mol Hum Reprod 11:189–194 11. Du GP, Zhang W, Wang L et al (2007) Identification of differ - entially expressed genes in endometrium during the window of implantation using suppression substractive hybridization. Zhon- ghua Fu Chan Ke Za Zhi 42:187–191 12. Barondes SH, Cooper DN, Gitt MA et al (1994) Galectins. Structure and function of a large family of animal lectins. J Biol Chem 269:20807–20810 13. Panjwani N (2014) Role of galectins in re-epitheliali- zation of wounds. Ann Transl Med 2:89. doi:10.3978/j. issn.2305-5839.2014.09.09 14. Rabinovich GA, Liu FT, Hirashima M (2007) An emerging role for galectins in tuning the immune response: lessons from exper- imental models of inflammatory disease, autoimmunity and can- cer. Scand J Immunol 66:143–158 15. Merlin J, Stechly L, de Beaucé S et al (2011) Galectin-3 regu- lates MUC1 and EGFR cellular distribution and EGFR down- stream pathways in pancreatic cancer cells. Oncogene 30:2514– 2525. doi:10.1038/onc.2010.631 16. Brustmann H, Riss D, Naude S (2003) Galectin-3 expression in normal, hyperplastic, and neoplastic endometrial tissues. Pathol Res Pract 199:151–158 17. Stewart CJ, Crook ML (2010) Galectin-3 expression in uterine endometrioid adenocarcinoma: comparison of staining in con- ventional tumor glands and in areas of MELF pattern myometrial invasion. Int J Gynecol Pathol 29:555–561 18. Dange MC, Srinivasan N, More SK et al (2014) Galectin-3 expressed on different lung compartments promotes organ spe- cific metastasis by facilitating arrest, extravasation and organ colonization via high affinity ligands on melanoma cells. Clin Exp Metastasis 31:661–673 19. Hu R, Jin H, Zhou S et al (2007) Proteomic analysis of hypoxia- induced responses in the syncytialization of human placental cell line BeWo. Placenta 28:399–407 20. Du GP, Zhang W, Wang L et al (2006) Expression of galectin-3 in human endometrium. Fudan Univ J Med Sci 02:143–146 21. Davidson PJ, Davis MJ, Patterson RJ et al (2002) Shuttling of galectin-3 between the nucleus and cytoplasm. Glycobiology 12:329–337 22. Yang H, Lei C, Cheng C et al (2012) The antiapoptotic effect of galectin-3 in human endometrial cells under the regulation of estrogen and progesterone. Biol Reprod 87:39. doi:10.1095/ biolreprod 23. Noyes RW, Hertig AT, Rock J et al (1975) Dating the endome- trial biopsy. Am J Obstet Gynecol 122:262–263 24. Khan KN, Masuzaki H, Fujishita A et al (2005) Interleukin- 6-and tumour necrosis factor alpha-mediated expression of hepatocyte growth factor by stromal cells and its involvement in the growth of endometriosis. Hum Reprod 20:2715–2723 25. Lei CX, Zhang W, Zhou JP et al (2009) Interactions between galectin-3 and integrinbeta3 in regulating endometrial cell prolif- eration and adhesion. Hum Reprod 24:2879–2889 26. Giudice LC, Kao LC (2004) Endometriosis. Lancet 364:1789–1799 27. Yang H, Taylor HS, Lei C et al (2011) Hormonal regulation of galectin 3 in trophoblasts and its effects on endometrium. Reprod Sci 18:1118–1127 28. Fazleabas AT (2006) A baboon model for inducing endometrio- sis. Methods Mol Med 121:95–99 29. Lessey BA, Palomino W A, Apparao KB et al (2006) Estrogen receptor-alpha (ER-alpha) and defects in uterine receptivity in women. Reprod Biol Endocrinol 4(Suppl 1):S9 30. Caserta D, Di Benedetto L, Bordi G et al (2014) Levels of galec- tin-3 and stimulation expressed gene 2 in the peritoneal fluid of women with endometriosis: a pilot study. Gynecol Endocrinol 29:1–4